Canaccord Genuity Maintains Buy on AngioDynamics, Lowers Price Target to $13
Canaccord Genuity Maintains Buy on AngioDynamics, Lowers Price Target to $13
Canaccord Genuity維持對angiodynamics的買入評級，將目標價調降至13美元。
Canaccord Genuity analyst William Plovanic maintains AngioDynamics (NASDAQ:ANGO) with a Buy and lowers the price target from $18 to $13.
Canaccord Genuity分析師William Plovanic維持對AngioDynamics（納斯達克：ANGO）的買入評級，將目標價從18美元下調至13美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。